Precisely. It's particularly difficult to run multiple trials of drugs for rare diseases -- there's a limited pool of patients available for these studies, and

Precisely. It's particularly difficult to run multiple trials of drugs for rare diseases -- there's a limited pool of patients available for these studies, and splitting them up between multiple studies makes it much more difficult for each of those studies to reach a statistically significant conclusion.